Shanghai Enlemay Biotechnology

Shanghai Enlemay Biotechnology is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative antibody-based therapeutics for cancer and autoimmune diseases. The company leverages its proprietary Enle-Mab platform to engineer next-generation biologics, including bispecific antibodies and immune checkpoint inhibitors. Its lead programs target the CD47/SIRPα pathway, aiming to enhance the innate immune system's ability to clear tumor cells while minimizing off-target effects such as anemia. Enlemay is headquartered in Shanghai and maintains a robust pipeline of candidates in various stages of clinical and preclinical development. The company is backed by prominent venture capital firms including Qiming Venture Partners and Matrix Partners China. Its lead candidate, EM-011, has demonstrated promising safety and efficacy profiles in early-stage clinical trials for hematologic malignancies.